First commercial medical cannabis export from Israel lands in Germany

Medical cannabis patients in Germany received a welcome gift for Christmas Eve on Thursday after Israel’s leading medical cannabis company, Panaxia, completed its first commercial export of medical cannabis products to the country.Earlier this month, Panaxia announced that they had become the first company in Israel to receive a commercial license from the Health Ministry to export medical cannabis to Germany.Germany is home to the world’s fastest growing medical cannabis market outside of the United States, with 120,000 patients already being treated using medical cannabis products, paying on average between 2-5 times the amount paid by Israeli patients. A spokesperson for Panaxia said they expect the German market to expand to 800 thousand over the next four years.Panaxia will begin selling a series of premium oil-based medical cannabis products in Germany under the Naxiva-Panaxol brand, which it shares with European pharma giant Neuraxpharm.

Unlike Israeli patients, who receive a prescription mainly based on THC and CBD levels, German doctors prescribe their patients specific products and strains, which makes the strategic marketing partnership with Neuraxpharm vital to Panaxia’s future success or failure in the country.

“Today we are celebrating a success that is the result of hard and continuous work that expresses the strength of Panaxia as a…
Medical cannabis patients in Germany received a welcome gift for Christmas Eve on Thursday after Israel’s leading medical cannabis company, Panaxia, completed its first commercial export of medical cannabis products to the country.Earlier this month, Panaxia announced that they had become the first company in Israel to receive a commercial license from the Health Ministry to export medical cannabis to Germany.Germany is home to the world’s fastest growing medical cannabis market outside of the United States, with 120,000 patients already being treated using medical cannabis products, paying on average between 2-5 times the amount paid by Israeli patients. A spokesperson for Panaxia said they expect the German market to expand to 800 thousand over the next four years.Panaxia will begin selling a series of premium oil-based medical cannabis products in Germany under the Naxiva-Panaxol brand, which it shares with European pharma giant Neuraxpharm.

Unlike Israeli patients, who receive a prescription mainly based on THC and CBD levels, German doctors prescribe their patients specific products and strains, which makes the strategic marketing partnership with Neuraxpharm vital to Panaxia’s future success or failure in the country.

“Today we are celebrating a success that is the result of hard and continuous work that expresses the strength of Panaxia as a…

Latest posts